Latest market price
321.34
+2.39+0.75%
PENQT55Penumbra, Inc.·NYSE
321.34+0.75%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E80.94EPS (ttm)3.97Insider Own3.76%Shs Outstand39.39MPerf Week-1.19%
Market Cap12.66BForward P/E54.10EPS next Y5.94Insider Trans0.00%Shs Float38.28MPerf Month1.19%
Enterprise Value12.18BPEG4.15EPS next Q1.44Short Float5.91%Perf Quarter-0.89%
Income157.00MP/S8.11EPS this Y23.47%Short Ratio6.66Perf Half Y-1.02%
Sales1.56BP/B7.99EPS next Y27.08%ROA7.75%Short Interest2.26MPerf YTD3.35%
Book/sh40.21P/C18.78EPS next 5Y19.52%ROE10.44%52W High362.41 -11.33%Perf Year38.78%
Cash/sh17.11P/FCF63.29EPS past 3/5Y—ROIC7.91%52W Low221.26 45.23%Perf 3Y66.43%
Dividend Est.—EV/EBITDA53.17Sales past 3/5Y18.35% 20.18%Gross Margin67.98%Volatility0.96% 0.68%Perf 5Y15.51%
Dividend TTM—EV/Sales7.80EPS Y/Y TTM-5.02%Oper. Margin12.13%ATR (14)2.50Perf 10Y334.54%
Dividend Ex-Date—Quick Ratio3.92Sales Y/Y TTM16.94%Profit Margin10.06%RSI (14)50.55Recom2.59
Dividend Gr. 3/5Y—Current Ratio5.89EPS Q/Q10.31%SMA200.06%Beta0.68Target Price320.00
Payout0.00%Debt/Eq0.12Sales Q/Q15.49%SMA500.28%Rel Volume1.33Prev Close318.95
Employees4,700LT Debt/Eq0.12EarningsFeb 24SMA200-1.83%Avg Volume348.07KPrice321.34
IPO DateSep 18, 2015Option/ShortYes / YesEPS/Sales Surpr.-11.09% 2.18%Net Debt/EBITDA-2.10Volume463,523Change0.75%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-06-26ReiteratedEvercore ISI GroupOutperform$335 → $320
May-07-26ReiteratedEvercore ISI GroupOutperform$360 → $335
Feb-26-26ReiteratedUBSBuy$335 → $374
Jan-20-26DowngradeCanaccord GenuityBuy → Hold$359 → $374
Jan-20-26DowngradeRBC CapitalOutperform → Sector Perform$355 → $374
Jan-16-26ReiteratedRobert W. Baird$345 → $374
Jan-16-26DowngradeNeedhamBuy → Hold
Jan-16-26DowngradeCitigroupBuy → Neutral
Jan-16-26DowngradeLeerink PartnersOutperform → Market Perform$263 → $374
Jan-16-26DowngradeBTIGBuy → Neutral$349
Latest News· Times ET
Oct-29-26
Oct-29-2604:27PM
Oct-20-26
Oct-17-26
Oct-15-26
Oct-08-26
Oct-06-26
Oct-01-26
Sep-30-26
Sep-29-26
Sep-16-26
Sep-11-26
Aug-30-26
Aug-26-26
Aug-25-26
Company

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,5601,4041,1951,059—————
Cost of Goods Sold Incl. D&A499461440376—————
Gross Profit1,060942755683—————
Selling, General and Administrative Excl. Other777663574506—————
Research and Development94909584—————
Other Operating Expense10019—————
Operating Income1891898674—————
Interest Expense0112—————
Unusual Expense
—————————
Non-Operating Income (Expense)2017-648—————
Net Income Before Taxes2082052180—————
Income Taxes50277-11—————
Consolidated Net Income1571781491—————
Net Income From Continuing Operations1571781491—————
Net Income1571781491—————
EPS (Recurring)3.994.570.362.37—————
EPS (Basic, Before Extraordinaries)3.994.570.362.37—————
EPS (Diluted)3.974.520.362.32—————
EBITDA22922446109—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio80.9468.79659.67108.42—————
Price To Sales Ratio8.038.647.759.03—————
Gross Margin67.9567.0963.1864.49—————
Operating Margin12.1213.467.206.99—————
Net Margin10.0612.681.178.59—————
Shares Outstanding39393938—————
Market Capitalization12,53212,1259,2629,559—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$379.48$335.97$292.47$248.97$205.46● Close Price0.00M1.29M2.59M3.88M5.17MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Grewal HarpreetDirectorApr 02 '26Sale328.2210032,8228,719Apr 06
Yuen MaggieChief Financial OfficerMar 02 '26Sale342.302,432832,47418,353Mar 04
Grewal HarpreetDirectorJan 06 '26Sale312.6418658,1518,230Jan 08
Wilder ThomasDirectorJan 02 '26Sale310.7218657,7940Jan 06
Bose AraniDirectorDec 11 '25Sale308.8215,0004,632,293258,462Dec 15
Roberts JohannaEVP, Gen. Counsel & SecretaryDec 05 '25Sale300.1330090,03963,836Dec 09
Grewal HarpreetDirectorDec 02 '25Sale292.9810029,2988,416Dec 03
Roberts JohannaEVP, Gen. Counsel & SecretaryDec 01 '25Sale294.94600176,96764,136Dec 03
Bose AraniDirectorNov 25 '25Sale300.197,5002,251,425275,261Nov 26
Roberts JohannaEVP, Gen. Counsel & SecretaryNov 25 '25Sale300.061,800540,10864,736Nov 26
Bose AraniDirectorNov 21 '25Sale290.567,5002,179,213282,761Nov 25
Roberts JohannaEVP, Gen. Counsel & SecretaryNov 10 '25Sale266.98600160,18963,657Nov 12
Grewal HarpreetDirectorNov 04 '25Sale227.5818642,3308,516Nov 06
Grewal HarpreetDirectorOct 02 '25Sale248.6118646,2418,702Oct 03
Roberts JohannaEVP, Gen. Counsel & SecretaryOct 01 '25Sale249.70600149,82264,257Oct 03
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.